Saltar al contenido
Merck

Neutrophil Extracellular Traps Initiate Gallstone Formation.

Immunity (2019-08-20)
Luis E Muñoz, Sebastian Boeltz, Rostyslav Bilyy, Christine Schauer, Aparna Mahajan, Navena Widulin, Anika Grüneboom, Irmgard Herrmann, Edgyda Boada, Manfred Rauh, Veit Krenn, Mona H C Biermann, Malgorzata J Podolska, Jonas Hahn, Jasmin Knopf, Christian Maueröder, Solomiya Paryzhak, Tetiana Dumych, Yi Zhao, Markus F Neurath, Markus H Hoffmann, Tobias A Fuchs, Moritz Leppkes, Georg Schett, Martin Herrmann
RESUMEN

The presence of gallstones (cholelithiasis) is a highly prevalent and severe disease and one of the leading causes of hospital admissions worldwide. Due to its substantial health impact, we investigated the biological mechanisms that lead to the formation and growth of gallstones. We show that gallstone assembly essentially requires neutrophil extracellular traps (NETs). We found consistent evidence for the presence of NETs in human and murine gallstones and describe an immune-mediated process requiring activation of the innate immune system for the formation and growth of gallstones. Targeting NET formation via inhibition of peptidyl arginine deiminase type 4 or abrogation of reactive oxygen species (ROS) production, as well as damping of neutrophils by metoprolol, effectively inhibit gallstone formation in vivo. Our results show that after the physicochemical process of crystal formation, NETs foster their assembly into larger aggregates and finally gallstones. These insights provide a feasible therapeutic concept to prevent cholelithiasis in patients at risk.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Colesterol, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Cytochalasin D, from Zygosporium mansonii, ≥98% (TLC and HPLC), powder
Sigma-Aldrich
Colchicina, BioReagent, suitable for plant cell culture, ≥95% (HPLC)
Sigma-Aldrich
Diphenyleneiodonium chloride, ≥98%
Sigma-Aldrich
PAD Inhibitor, Cl-amidine, Cl-amidine is a cell-permeable pan PAD inhibitor (IC₅₀ = 0.8, 6.2, and 5.9 µM for PAD1, PAD3, and PAD4, respectively). Inactivates the calcium bound form of PAD4 in an irreversible manner.
Sigma-Aldrich
GSK484, ≥98% (HPLC)